Marie Beylot-Barry, MD, PhD

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Stopping mogamulizumab after a strong response — then resuming it at relapse — emerged as a viable strategy for select patients with Sézary syndrome.

A planned mogamulizumab break emerged as best suited to older patients not bound for transplant, pending prospective confirmation.